Watch | OncLive

Trending Videos

KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

Commentary

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

Commentary

Sequencing and Emerging Targets Revamp the Platinum-Resistant Ovarian Cancer Treatment Paradigm: With David O’Malley, MD

Sequencing and Emerging Targets Revamp the Platinum-Resistant Ovarian Cancer Treatment Paradigm: With David O’Malley, MD

Commentary

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

Commentary

Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD (VIDEO)

Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD (VIDEO)

Commentary

FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD

FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD

Commentary

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Commentary

ADCs, Metabolic Health Strategies, and Lifestyle Interventions Add up to Holistic TNBC Care: With Chandler Park, MD; and Neil M. Iyengar, MD

ADCs, Metabolic Health Strategies, and Lifestyle Interventions Add up to Holistic TNBC Care: With Chandler Park, MD; and Neil M. Iyengar, MD

Commentary

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

Commentary

The Power of Patient-Provider Dialogue to Help Shape First-Line Treatment for Ph+ CML in Chronic Phase

News

Shorts

Charles E. Geyer, MD

Noting ILD/Radiation Pneumonitis Outcomes From DESTINY-Breast05

5 days ago

by

Charles E. Geyer, MD

Chronic Neutropenia

Exploring Mavorixafor in Chronic Neutropenia Management

5 days ago

by

David Sykes, MD, PhD

Aaron Gerds, MD, MS, breaks down considerations for selecting a JAK inhibitor in the treatment of patients with myelofibrosis.

Selecting a JAK Inhibitor in Myelofibrosis

6 days ago

by

Aaron Gerds, MD, MS

Midhun Malla, MD

Spotlighting the Importance of Biomarker Testing in GI Cancer

6 days ago

by

Midhun Malla, MD

Philip A. Philip, MD

Highlighting Appendix Cancer Awareness Month

7 days ago

by

Philip A. Philip, MD

Ranee Mehra, MD

Examining Amivantamab in Head and Neck Cancer

7 days ago

by

Ranee Mehra, MD

Zulfa Omer, MD

Comparing Mechanisms of Action for BTK Degraders and Inhibitors

10 days ago

by

Zulfa Omer, MD

Alan L. Ho, MD, PhD

Highlighting a Phase 3 Trial of Ozuriftamab Vedotin in HPV-Associated OPSCC

10 days ago

by

Alan L. Ho, MD, PhD

Breast Cancer Briefing

Individualizing Efforts to Lower Recurrence Risk in Breast Cancer

10 days ago

by

Sara Nunnery, MD, MSCI(+1 more)

Uma Borate, MBBS, MS

Unpacking Data for Shorter Venetoclax Schedules in AML

10 days ago

by

Uma Borate, MBBS, MS

Expert Conversations

OncChats

Peer Exchange

OncLive Insights

Shows & Podcasts

How This Is Building Me

Two Onc Docs

Oncology Unplugged With Dr Chandler Park

Cancer, Character, and Calling

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

Breast Cancer Briefing

News & Analysis

OncLive News Network®

OncLive TV

Rapid Readouts

Biomarker Consortium

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

CARiBOU Regimen Drives Complete Metabolic Responses in First-Line Mantle Cell Lymphoma

Five Under 5: Top Oncology Videos for the Week of 8/31/26

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC